Sara A. Monaghan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara A. Monaghan has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Al-Attar
Department of Pathology University of Pittsburgh Pittsburgh Pennsylvania USA
6 shared publications Wendy Shallenberger
UPMC Pittsburgh Pennsylvania USA
3 shared publicationsEleni Linskens
Department of Clinical Biology, Laboratory Hematology University Hospital Brussels Brussels Belgium
2 shared publications- Horatiu Olteanu
Mayo Clinic, Rochester, Minnesota, United States
2 shared publications - Nidhi Aggarwal
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, USA
2 shared publications - Paul K. Wallace
Department of Microbiology, HB7556, Dartmouth Medical School, 1 Medical Center Drive, Lebanon, NH 03756, USA
2 shared publications
Latest Publications
- 17 March 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-5
T-prolymphocytic leukemia with three distinct immunophenotypic subsets
T-prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell neoplasm usually affecting older adults, often presenting with marked leukocytosis and splenomegaly. It is characteristically associated with recurrent chromosome 14 rearrangements that drive overexpression of TCL1 family oncogenes. Neoplastic cells generally show a mature T-cell immunophenotype with preserved pan-T cell markers, most commonly CD4⁺ with or without CD8 expression. Although T-PLL can harbor substantial genetic complexity that may lead to subclonal evolution, overt phenotypic diversification into distinctly separable abnormal T-cell populations within a single case of T-PLL is rarely documented, particularly among those characterized by multiparametric flow cytometry. This brief report describes a patient with T-PLL in whom three distinct abnormal T-cell subsets were delineated by flow cytometric analysis using TRBC1. This case illustrates striking intratumoral heterogeneity in a neoplasm that is typically regarded as phenotypically uniform and demonstrates the utility of TRBC1 analysis in refining diagnostic assessment.
- 17 March 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-5
T-prolymphocytic leukemia with three distinct immunophenotypic subsets
T-prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell neoplasm usually affecting older adults, often presenting with marked leukocytosis and splenomegaly. It is characteristically associated with recurrent chromosome 14 rearrangements that drive overexpression of TCL1 family oncogenes. Neoplastic cells generally show a mature T-cell immunophenotype with preserved pan-T cell markers, most commonly CD4⁺ with or without CD8 expression. Although T-PLL can harbor substantial genetic complexity that may lead to subclonal evolution, overt phenotypic diversification into distinctly separable abnormal T-cell populations within a single case of T-PLL is rarely documented, particularly among those characterized by multiparametric flow cytometry. This brief report describes a patient with T-PLL in whom three distinct abnormal T-cell subsets were delineated by flow cytometric analysis using TRBC1. This case illustrates striking intratumoral heterogeneity in a neoplasm that is typically regarded as phenotypically uniform and demonstrates the utility of TRBC1 analysis in refining diagnostic assessment.
- Open Access
- 9 February 2026
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (2) , 73-76
COMIP‐001: A clinical 13‐antibody, 12‐color flow cytometry panel for optimized immunophenotyping of T/ NK cells in human leukemia and lymphoma diagnostics
The objective of this 12‐color/13‐antibody single‐tube panel is to assist in the diagnosis of T/NK‐cell leukemias and lymphomas. In the clinical setting, the absence of a standardized T/NK‐cell panel limits inter‐laboratory data comparability, contributes to diagnostic variability, and results in redundant efforts across laboratories to design and validate panels for flow cytometry. Developing and promoting a panel that allows for rapid and fairly comprehensive labeling of surface T/NK‐cell markers, including the anti‐T‐cell receptor β‐chain constant region 1 (TRBC1) antibody, will streamline the workflow by establishing a standard immunophenotyping T/NK‐cell panel for detecting neoplastic T/NK cells and lay the foundation for future COMIPs.
- 9 February 2026
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (2) , 73-76
Open AccessCOMIP‐001: A clinical 13‐antibody, 12‐color flow cytometry panel for optimized immunophenotyping of T/ NK cells in human leukemia and lymphoma diagnostics
The objective of this 12‐color/13‐antibody single‐tube panel is to assist in the diagnosis of T/NK‐cell leukemias and lymphomas. In the clinical setting, the absence of a standardized T/NK‐cell panel limits inter‐laboratory data comparability, contributes to diagnostic variability, and results in redundant efforts across laboratories to design and validate panels for flow cytometry. Developing and promoting a panel that allows for rapid and fairly comprehensive labeling of surface T/NK‐cell markers, including the anti‐T‐cell receptor β‐chain constant region 1 (TRBC1) antibody, will streamline the workflow by establishing a standard immunophenotyping T/NK‐cell panel for detecting neoplastic T/NK cells and lay the foundation for future COMIPs.
- 25 December 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (4) , 299-300
Authors' Response to Letter from Khanolkar and Ahmed concerning our article “An unusual pattern observed upon the addition of CD79b to a flow cytometry B‐cell lymphoma panel” (Panakkal et al., 2025). Cytometry Part B: Clinical Cytometry . DOI: 10.1002/cyto.b.22246. PMID : 40657818
- 25 December 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (4) , 299-300
Authors' Response to Letter from Khanolkar and Ahmed concerning our article “An unusual pattern observed upon the addition of CD79b to a flow cytometry B‐cell lymphoma panel” (Panakkal et al., 2025). Cytometry Part B: Clinical Cytometry . DOI: 10.1002/cyto.b.22246. PMID : 40657818
- 30 October 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (2) , 102-117
International Clinical Cytometry Society 2023 workload survey of clinical flow cytometry laboratories
Clinical flow cytometry laboratories are facing rising test volumes, greater assay complexity, and increasing requirements for quality control and assay validation. In response, the International Clinical Cytometry Society (ICCS) conducted a workload survey in early 2023 to gather updated information on assay volumes, complexity, staffing, and technology. Data analysis focused on identifying correlations between length of time to introduce new assays and other factors as a means to gain insight about laboratories that seem to be either adapting or struggling. Flow cytometry assays were categorized into 3 levels of technical/interpretative complexity: high (e.g., measurable/minimal residual disease (MRD assays)), moderate (e.g., leukemia/lymphoma assays (Assays L&L ), excluding MRD assays), and low (e.g., CD4 count). Annual assays per staff member were calculated according to staff involved in case sign‐out (Staff Signout ) or other laboratory operations (Staff LabOps ). Respondents were from 101 laboratories in the United States (69.3%), Canada (4.0%), and other countries (26.7%). Low, moderate, and high technical/interpretative complexity assays were performed in 85.1%, 97.0%, and 47.5% of all laboratories, respectively. Median annual total assays (Assays Total ) per laboratory were 3515 and, based on complexity, were 1518.5 (low), 1808.8 (moderate), and 350 (high). Among all laboratories, the median time (interquartile range) to introduce new Assays L&L was 6 mos. (4–12 mos.), to introduce MRD assays was 11 mos. (5–12 mos.), and to validate/go‐live with new cytometers was 8 mos. (4–12 mos.); these times positively correlated with each other. This study confirmed significantly increased workload since the prior ICCS 2013 workload survey with a concurrent decrease in Staff LabOps . Faster introduction of new assays correlated with other successes, including quicker validation of and going live with new cytometers. Among all laboratories, those that performed myeloid MRD assays versus those that did not were also found to be faster to introduce new assays. The need for sufficient staffing has been emphasized because laboratories with both higher annual volumes of myeloma MRD assays and higher ratios of Assays Total per Staff LabOps were slower to introduce new assays. “Lack of staff and/or time dedicated or protected for assay development” and, more generally, “staff number” were the most commonly identified major barriers for new assay development, with the former specifically linked to slower introduction of new assays among all laboratories.
- 30 October 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (2) , 102-117
International Clinical Cytometry Society 2023 workload survey of clinical flow cytometry laboratories
Clinical flow cytometry laboratories are facing rising test volumes, greater assay complexity, and increasing requirements for quality control and assay validation. In response, the International Clinical Cytometry Society (ICCS) conducted a workload survey in early 2023 to gather updated information on assay volumes, complexity, staffing, and technology. Data analysis focused on identifying correlations between length of time to introduce new assays and other factors as a means to gain insight about laboratories that seem to be either adapting or struggling. Flow cytometry assays were categorized into 3 levels of technical/interpretative complexity: high (e.g., measurable/minimal residual disease (MRD assays)), moderate (e.g., leukemia/lymphoma assays (Assays L&L ), excluding MRD assays), and low (e.g., CD4 count). Annual assays per staff member were calculated according to staff involved in case sign‐out (Staff Signout ) or other laboratory operations (Staff LabOps ). Respondents were from 101 laboratories in the United States (69.3%), Canada (4.0%), and other countries (26.7%). Low, moderate, and high technical/interpretative complexity assays were performed in 85.1%, 97.0%, and 47.5% of all laboratories, respectively. Median annual total assays (Assays Total ) per laboratory were 3515 and, based on complexity, were 1518.5 (low), 1808.8 (moderate), and 350 (high). Among all laboratories, the median time (interquartile range) to introduce new Assays L&L was 6 mos. (4–12 mos.), to introduce MRD assays was 11 mos. (5–12 mos.), and to validate/go‐live with new cytometers was 8 mos. (4–12 mos.); these times positively correlated with each other. This study confirmed significantly increased workload since the prior ICCS 2013 workload survey with a concurrent decrease in Staff LabOps . Faster introduction of new assays correlated with other successes, including quicker validation of and going live with new cytometers. Among all laboratories, those that performed myeloid MRD assays versus those that did not were also found to be faster to introduce new assays. The need for sufficient staffing has been emphasized because laboratories with both higher annual volumes of myeloma MRD assays and higher ratios of Assays Total per Staff LabOps were slower to introduce new assays. “Lack of staff and/or time dedicated or protected for assay development” and, more generally, “staff number” were the most commonly identified major barriers for new assay development, with the former specifically linked to slower introduction of new assays among all laboratories.
- 15 September 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (1) , 11-21
Ad hoc antibody modification of a validated flow cytometric immunophenotyping panel—recommendations and safeguards for clinical laboratories
Immunophenotyping by flow cytometry is a valuable test providing important information in a timely manner. In clinical laboratories, it is performed using validated antibody panels designed to ensure consistent and accurate results. However, unforeseen situations, such as unique or unusual immunophenotypes, or supply chain issues, may necessitate ad hoc modifications to these panels. This manuscript provides guidance for performing minor modifications, such as substituting or adding one or two antibodies, while maintaining the integrity of the assay. These modifications are intended for rare clinical situations and are not substitutes for the full validation protocols outlined in CLSI H62. An example of this would be a patient with a rare, but not uncommon, situation in which a B cell lymphoma lacks expression of CD19, CD20, and surface light chains, such that the lineage of the neoplastic cells cannot be determined without a straightforward addition or substitution of another marker into a laboratory's available panel. The recommendations and best practices herein aim to optimize patient care by allowing laboratories to adapt to unique clinical scenarios without compromising assay performance and are not a way to permanently modify the assay. Key considerations include assessing the impact on fluorescence compensation, antibody binding, assay sensitivity, and overall assay performance. The manuscript provides limitations for the extent of modifications, examples, and troubleshooting strategies to ensure reliable results when ad hoc changes are made. Proper documentation with review and approval by laboratory medical directors is recommended to mitigate risks associated with these modifications.
- 15 September 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (1) , 11-21
Ad hoc antibody modification of a validated flow cytometric immunophenotyping panel—recommendations and safeguards for clinical laboratories
Immunophenotyping by flow cytometry is a valuable test providing important information in a timely manner. In clinical laboratories, it is performed using validated antibody panels designed to ensure consistent and accurate results. However, unforeseen situations, such as unique or unusual immunophenotypes, or supply chain issues, may necessitate ad hoc modifications to these panels. This manuscript provides guidance for performing minor modifications, such as substituting or adding one or two antibodies, while maintaining the integrity of the assay. These modifications are intended for rare clinical situations and are not substitutes for the full validation protocols outlined in CLSI H62. An example of this would be a patient with a rare, but not uncommon, situation in which a B cell lymphoma lacks expression of CD19, CD20, and surface light chains, such that the lineage of the neoplastic cells cannot be determined without a straightforward addition or substitution of another marker into a laboratory's available panel. The recommendations and best practices herein aim to optimize patient care by allowing laboratories to adapt to unique clinical scenarios without compromising assay performance and are not a way to permanently modify the assay. Key considerations include assessing the impact on fluorescence compensation, antibody binding, assay sensitivity, and overall assay performance. The manuscript provides limitations for the extent of modifications, examples, and troubleshooting strategies to ensure reliable results when ad hoc changes are made. Proper documentation with review and approval by laboratory medical directors is recommended to mitigate risks associated with these modifications.
- 14 July 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 108 (6) , 488-489
An unusual pattern observed upon the addition of CD79b to a flow cytometry B‐cell lymphoma panel
- 14 July 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 108 (6) , 488-489
An unusual pattern observed upon the addition of CD79b to a flow cytometry B‐cell lymphoma panel
- 21 August 2024
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 108 (3) , 252-266
Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines
The Clinical and Laboratory Standards Institute (CLSI) H62—Validation of Assays Performed by Flow Cytometry guideline, released in 2021, provides recommendations for platform workflow and quality system essentials, instrument setup and standardization, assay development and optimization and fit‐for‐purpose analytical method validation. In addition, CLSI H62 includes some recommendations for the validation strategies after a validated flow cytometric method has been modified. This manuscript builds on those recommendations and discusses the impact of different types of assay modifications on assay performance. Recommendations regarding which validation parameters to evaluate depending on the type of modification are provided. The impact of assay modification on the assay's intended use is discussed. When recommending minor deviations from the CLSI H62 process for a laboratory‐initiated assay revision (e.g., specimen numbers for sensitivity, specificity, or precision studies), a rationale based on expert opinion is provided with the understanding that not every laboratory, assay type, and circumstance can be comprehensively addressed in this paper. These recommendations are meant as a practical recommendation and are not intended to be restrictive, prescriptive, or understood as necessarily sufficient to meet every specific requirement from regulatory bodies (e.g., FDA or New York State Department of Health).
- 21 August 2024
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 108 (3) , 252-266
Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines
The Clinical and Laboratory Standards Institute (CLSI) H62—Validation of Assays Performed by Flow Cytometry guideline, released in 2021, provides recommendations for platform workflow and quality system essentials, instrument setup and standardization, assay development and optimization and fit‐for‐purpose analytical method validation. In addition, CLSI H62 includes some recommendations for the validation strategies after a validated flow cytometric method has been modified. This manuscript builds on those recommendations and discusses the impact of different types of assay modifications on assay performance. Recommendations regarding which validation parameters to evaluate depending on the type of modification are provided. The impact of assay modification on the assay's intended use is discussed. When recommending minor deviations from the CLSI H62 process for a laboratory‐initiated assay revision (e.g., specimen numbers for sensitivity, specificity, or precision studies), a rationale based on expert opinion is provided with the understanding that not every laboratory, assay type, and circumstance can be comprehensively addressed in this paper. These recommendations are meant as a practical recommendation and are not intended to be restrictive, prescriptive, or understood as necessarily sufficient to meet every specific requirement from regulatory bodies (e.g., FDA or New York State Department of Health).
- 12 February 2022
- Published by Elsevier in Human Pathology
- Vol. 123, 11-19
Distinct pathologic feature of myeloid neoplasm with t(v;11p15); NUP98 rearrangement
- 12 February 2022
- Published by Elsevier in Human Pathology
- Vol. 123, 11-19
Distinct pathologic feature of myeloid neoplasm with t(v;11p15); NUP98 rearrangement
- 13 October 2021
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 157 (4) , 546-553
A Machine Learning Approach to the Classification of Acute Leukemias and Distinction From Nonneoplastic Cytopenias Using Flow Cytometry Data
Objectives: Flow cytometry (FC) is critical for the diagnosis and monitoring of hematologic malignancies. Machine learning (ML) methods rapidly classify multidimensional data and should dramatically improve the efficiency of FC data analysis. We aimed to build a model to classify acute leukemias, including acute promyelocytic leukemia (APL), and distinguish them from nonneoplastic cytopenias. We also sought to illustrate a method to identify key FC parameters that contribute to the model’s performance. Methods: Using data from 531 patients who underwent evaluation for cytopenias and/or acute leukemia, we developed an ML model to rapidly distinguish among APL, acute myeloid leukemia/not APL, acute lymphoblastic leukemia, and nonneoplastic cytopenias. Unsupervised learning using gaussian mixture model and Fisher kernel methods were applied to FC listmode data, followed by supervised support vector machine classification. Results: High accuracy (ACC, 94.2%; area under the curve [AUC], 99.5%) was achieved based on the 37-parameter FC panel. Using only 3 parameters, however, yielded similar performance (ACC, 91.7%; AUC, 98.3%) and highlighted the significant contribution of light scatter properties. Conclusions: Our findings underscore the potential for ML to automatically identify and prioritize FC specimens that have critical results, including APL and other acute leukemias.
- 13 October 2021
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 157 (4) , 546-553
A Machine Learning Approach to the Classification of Acute Leukemias and Distinction From Nonneoplastic Cytopenias Using Flow Cytometry Data
Objectives: Flow cytometry (FC) is critical for the diagnosis and monitoring of hematologic malignancies. Machine learning (ML) methods rapidly classify multidimensional data and should dramatically improve the efficiency of FC data analysis. We aimed to build a model to classify acute leukemias, including acute promyelocytic leukemia (APL), and distinguish them from nonneoplastic cytopenias. We also sought to illustrate a method to identify key FC parameters that contribute to the model’s performance. Methods: Using data from 531 patients who underwent evaluation for cytopenias and/or acute leukemia, we developed an ML model to rapidly distinguish among APL, acute myeloid leukemia/not APL, acute lymphoblastic leukemia, and nonneoplastic cytopenias. Unsupervised learning using gaussian mixture model and Fisher kernel methods were applied to FC listmode data, followed by supervised support vector machine classification. Results: High accuracy (ACC, 94.2%; area under the curve [AUC], 99.5%) was achieved based on the 37-parameter FC panel. Using only 3 parameters, however, yielded similar performance (ACC, 91.7%; AUC, 98.3%) and highlighted the significant contribution of light scatter properties. Conclusions: Our findings underscore the potential for ML to automatically identify and prioritize FC specimens that have critical results, including APL and other acute leukemias.
- Open Access
- 28 January 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (9) , 1965-1974
Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide
Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome. However, there is concern for increased myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) associated with LEN. Thus, bone marrow morphology and cytogenetics studies from 40 patients were evaluated for early signs of MDS prior to therapy, during therapy and at follow-up. Newly diagnosed patients with MM treated with LEN and dexamethasone (LD) alone or followed by autologous stem cell transplant (LD/ASCT), or patients with relapsed/refractory MM treated with LEN, bendamustine and dexamethasone (BLD) were included. One patient developed MDS. Baseline prevalence of mild morphologic myelodysplasia was highest in pretreated patients with MM (BLD, 71%), but was also seen in newly diagnosed patients (LD and LD/ASCT, 17%). The prevalence of myelodysplasia did not increase over time. Thus, this study did not reveal rapidly emerging MDS in 39 of 40 patients with MM treated with LEN. The development of MDS in one patient suggests that longer follow-up is needed for all.
- 28 January 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (9) , 1965-1974
Open AccessLongitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide
Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome. However, there is concern for increased myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) associated with LEN. Thus, bone marrow morphology and cytogenetics studies from 40 patients were evaluated for early signs of MDS prior to therapy, during therapy and at follow-up. Newly diagnosed patients with MM treated with LEN and dexamethasone (LD) alone or followed by autologous stem cell transplant (LD/ASCT), or patients with relapsed/refractory MM treated with LEN, bendamustine and dexamethasone (BLD) were included. One patient developed MDS. Baseline prevalence of mild morphologic myelodysplasia was highest in pretreated patients with MM (BLD, 71%), but was also seen in newly diagnosed patients (LD and LD/ASCT, 17%). The prevalence of myelodysplasia did not increase over time. Thus, this study did not reveal rapidly emerging MDS in 39 of 40 patients with MM treated with LEN. The development of MDS in one patient suggests that longer follow-up is needed for all.